Cosibelimab gets a guideline boost for skin cancer. The NCCN has elevated cosibelimab (Unloxcyt) to a Category 2A preferred option for patients with locally advanced cutaneous squamous cell carcinoma (CSCC) who aren't candidates for curative surgery or radiation. This builds on its earlier Category 2A designation for metastatic CSCC, backed by strong trial data showing durable responses.
The National Comprehensive Cancer Network (NCCN) has upgraded cosibelimab (Unloxcyt), a PD-L1 inhibitor, to a Category 2A preferred treatment option for patients with locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radiation. This latest designation expands on the drug's existing Category 2A status for metastatic CSCC, granted in 2025, and follows the FDA's December 2024 approval of cosibelimab for both locally advanced and metastatic CSCC.
The upgrade is backed by data from the pivotal phase 1 Study CK-301-101, which demonstrated clinically meaningful and durable responses in the locally advanced patient cohort. Across both CSCC cohorts, immune-related adverse events were manageable, with no grade 4 or 5 events reported.
By the Numbers:
Why it matters: For patients with locally advanced CSCC who have limited surgical or radiation options, cosibelimab's Category 2A preferred NCCN designation signals strong clinical confidence in the drug as a frontline immunotherapy choice — giving oncologists clearer guidance and potentially broadening patient access to this treatment.
